Literature DB >> 19918345

Randomized trials of prostate cancer screening.

Stacy Loeb1, Alan W Partin.   

Abstract

Entities:  

Year:  2009        PMID: 19918345      PMCID: PMC2777067     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


× No keyword cloud information.
  11 in total

1.  Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.

Authors:  Paul F Pinsky; Gerald L Andriole; Barnett S Kramer; Richard B Hayes; Philip C Prorok; John K Gohagan
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

2.  Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.

Authors:  Ingrid W van der Cruijsen-Koeter; Monique J Roobol; Mark F Wildhagen; T H van der Kwast; W J Kirkels; Fritz H Schröder
Journal:  Urology       Date:  2006-09       Impact factor: 2.649

3.  Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.

Authors:  Gunnar Aus; Svante Bergdahl; Pär Lodding; Hans Lilja; Jonas Hugosson
Journal:  Eur Urol       Date:  2006-07-28       Impact factor: 20.096

Review 4.  Screening for breast cancer with mammography.

Authors:  P C Gøtzsche; M Nielsen
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

5.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Authors:  P C Prorok; G L Andriole; R S Bresalier; S S Buys; D Chia; E D Crawford; R Fogel; E P Gelmann; F Gilbert; M A Hasson; R B Hayes; C C Johnson; J S Mandel; A Oberman; B O'Brien; M M Oken; S Rafla; D Reding; W Rutt; J L Weissfeld; L Yokochi; J K Gohagan
Journal:  Control Clin Trials       Date:  2000-12

6.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

7.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

8.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.

Authors:  W J Catalona; D S Smith; T L Ratliff; J W Basler
Journal:  JAMA       Date:  1993-08-25       Impact factor: 56.272

9.  Do men know that they have had a prostate-specific antigen test? Accuracy of self-reports of testing at 2 sites.

Authors:  Evelyn C Y Chan; Sally W Vernon; Chul Ahn; Anthony Greisinger
Journal:  Am J Public Health       Date:  2004-08       Impact factor: 9.308

10.  Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?

Authors:  Brenda E Sirovich; Lisa M Schwartz; Steven Woloshin
Journal:  JAMA       Date:  2003-03-19       Impact factor: 56.272

View more
  2 in total

1.  What is the true mortality benefit of prostate-specific antigen screening?

Authors:  Stacy Loeb; Alan W Partin
Journal:  Rev Urol       Date:  2010

2.  Update of randomized trials for prostate cancer screening.

Authors:  Annelies Vellekoop; Stacy Loeb
Journal:  Rev Urol       Date:  2013
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.